newsfilter
← Latest News
GlobeNewswire·

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status

Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum